Peptone Ltd is a London-based company that specializes in developing artificial intelligence solutions aimed at addressing protein development challenges within the biotechnology, biopharmaceutical, and life sciences sectors. Established in 2016, Peptone focuses on the discovery of novel therapeutics, particularly targeting intrinsically disordered proteins. The company offers a range of services, including antibody design and optimization, a comprehensive protein database, and automated thermos-stability engineering. Its proprietary platform, CassandraAI, facilitates in silico protein engineering, enhancing the efficiency of protein development processes. Peptone's advanced protein engineering system addresses complex tasks such as anomaly detection and risk assessment, enabling clients to identify optimal strategies for resolving potential failures. This capability allows users to select suitable commercial partners to produce high-quality molecules more rapidly and cost-effectively than traditional methods employed in the pharmaceutical industry.
Koneksa Health Inc. is a healthcare data analytics company focused on enhancing clinical studies and disease research through the use of remotely generated patient data. The company's software, Koneksa Compare, facilitates the collection, visualization, and analysis of patient-generated data, incorporating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires. This platform allows pharmaceutical and biotech companies, as well as academic researchers, to make informed decisions and regulatory claims based on objective data. Koneksa also provides biometric devices that generate electronic clinical outcome assessments and offers a dashboard for monitoring patient engagement, which includes reminders for study subjects. Founded in 2013 and headquartered in New York, Koneksa has an additional office in London, United Kingdom.
H1 is a healthcare data analytics company based in New York, founded in 2017. It offers a global platform that connects life sciences companies, hospitals, academic medical centers, and health systems with healthcare providers, clinical research opportunities, and industry experts. The platform focuses on delivering real-time data to support decision-making throughout the therapeutic development process, from fundraising to product launch. By providing access to comprehensive information on healthcare professionals and institutions, H1 facilitates connections within the healthcare ecosystem, enabling organizations and professionals to gain live insights that accelerate the discovery and development of therapies aimed at combating diseases.
Flywheel.io is a cloud-based data management platform tailored for biomedical research and collaboration. Founded in 2012 and headquartered in Minneapolis, Minnesota, the company provides a suite of tools designed to enhance the workflow of scientists and researchers. Its platform supports medical imaging, scientific computation, and content management, enabling users to capture, manage, and analyze research data efficiently. By utilizing cloud scalability and automation, Flywheel facilitates collaborative research, machine learning applications, and multicenter studies, which help organizations streamline their research processes. The platform, featuring a modern web interface and extensible compute engine, aims to eliminate bottlenecks in innovation, allowing researchers to focus on scientific discovery rather than IT challenges.
Dopavision is a therapeutic company developing a digital therapeutic for myopia. Myopia, or shortsightedness, is a condition where the visual image is focused in front of the retina, instead of on the retina itself, as it should. People with myopia have good near sight vision but poor distance vision. Dopavision is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated with the use of a smartphone. Myopia is a visual condition that affects on average every third person globally, a share that has increased rapidly during the last two decades. The goal of the Berlin-based startup is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Founded in 2017, Dopavision GmbH is supported by the German government via the “Industrie-in-Klinik” program of the BMBF (Federal Ministry of Education and Research) with the amount of € 1.4 million over three years.
NuvoAir AB, founded in 2015 and based in Stockholm, Sweden, is a medical technology company focused on monitoring lung function through its Air Next home spirometer. The company operates an online platform to provide its products and services. NuvoAir Medical offers a comprehensive care model that integrates advanced monitoring technology and analytics with evidence-based interventions for managing chronic heart and lung conditions. This approach emphasizes personalized care, delivered by a multidisciplinary team, and collaborates with health plans and risk-bearing entities to implement flexible payment arrangements. By focusing on value-based specialty management, NuvoAir aims to improve patient outcomes while reducing healthcare costs.
Flywheel.io is a cloud-based data management platform tailored for biomedical research and collaboration. Founded in 2012 and headquartered in Minneapolis, Minnesota, the company provides a suite of tools designed to enhance the workflow of scientists and researchers. Its platform supports medical imaging, scientific computation, and content management, enabling users to capture, manage, and analyze research data efficiently. By utilizing cloud scalability and automation, Flywheel facilitates collaborative research, machine learning applications, and multicenter studies, which help organizations streamline their research processes. The platform, featuring a modern web interface and extensible compute engine, aims to eliminate bottlenecks in innovation, allowing researchers to focus on scientific discovery rather than IT challenges.
Peptone Ltd is a London-based company that specializes in developing artificial intelligence solutions aimed at addressing protein development challenges within the biotechnology, biopharmaceutical, and life sciences sectors. Established in 2016, Peptone focuses on the discovery of novel therapeutics, particularly targeting intrinsically disordered proteins. The company offers a range of services, including antibody design and optimization, a comprehensive protein database, and automated thermos-stability engineering. Its proprietary platform, CassandraAI, facilitates in silico protein engineering, enhancing the efficiency of protein development processes. Peptone's advanced protein engineering system addresses complex tasks such as anomaly detection and risk assessment, enabling clients to identify optimal strategies for resolving potential failures. This capability allows users to select suitable commercial partners to produce high-quality molecules more rapidly and cost-effectively than traditional methods employed in the pharmaceutical industry.
Aspen RxHealth is a Tampa, Florida-based company that provides an online platform designed to connect licensed pharmacists with patients requiring enhanced medication services. Through its app-based technology, Aspen RxHealth facilitates direct patient care by matching pharmacists to patients based on various social and clinical criteria, such as language and medication regimens. This platform enables health plans and providers to link their patients with a community of pharmacists who can deliver clinical services tailored to individual needs. The services offered include comprehensive medication reviews and targeted medication interventions, all aimed at optimizing communication and improving patient care.
H1 is a healthcare data analytics company based in New York, founded in 2017. It offers a global platform that connects life sciences companies, hospitals, academic medical centers, and health systems with healthcare providers, clinical research opportunities, and industry experts. The platform focuses on delivering real-time data to support decision-making throughout the therapeutic development process, from fundraising to product launch. By providing access to comprehensive information on healthcare professionals and institutions, H1 facilitates connections within the healthcare ecosystem, enabling organizations and professionals to gain live insights that accelerate the discovery and development of therapies aimed at combating diseases.
Koneksa Health Inc. is a healthcare data analytics company focused on enhancing clinical studies and disease research through the use of remotely generated patient data. The company's software, Koneksa Compare, facilitates the collection, visualization, and analysis of patient-generated data, incorporating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires. This platform allows pharmaceutical and biotech companies, as well as academic researchers, to make informed decisions and regulatory claims based on objective data. Koneksa also provides biometric devices that generate electronic clinical outcome assessments and offers a dashboard for monitoring patient engagement, which includes reminders for study subjects. Founded in 2013 and headquartered in New York, Koneksa has an additional office in London, United Kingdom.
H1 is a healthcare data analytics company based in New York, founded in 2017. It offers a global platform that connects life sciences companies, hospitals, academic medical centers, and health systems with healthcare providers, clinical research opportunities, and industry experts. The platform focuses on delivering real-time data to support decision-making throughout the therapeutic development process, from fundraising to product launch. By providing access to comprehensive information on healthcare professionals and institutions, H1 facilitates connections within the healthcare ecosystem, enabling organizations and professionals to gain live insights that accelerate the discovery and development of therapies aimed at combating diseases.
Vineti, Inc. is a technology company that specializes in developing solutions for the therapeutic delivery of personalized medicine, particularly focusing on cell and gene therapies. Founded in 2016 and headquartered in San Francisco, California, with additional offices in Bethesda, Maryland, and Yerevan, Armenia, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform streamlines and automates patient-centric supply chains, facilitating the efficient management of operations, manufacturing, quality control, and regulatory compliance for advanced therapies, including CAR-T cell therapies for late-stage cancer. Vineti's solutions aim to enhance patient access to life-saving treatments while addressing the challenges faced by patients, healthcare providers, pharmaceutical companies, and regulators in the commercialization of personalized medicine. By providing tools for supply chain orchestration and maintaining an audit trail for the handling of cell products, Vineti positions itself as a critical player in the evolving landscape of personalized therapeutics.
RxVantage is OpenTable.com for pharma reps (and other medical vendors) looking to access physicians. The company's cloud-based platform improves patient outcomes and enhances the relationship between medical representatives and physicians’ offices. The Problem: The pharmaceutical industry spends $60 billion per year marketing, most of which is directed to the physicians who determine how the $325 billion that Americans spend each year on prescription drugs will be allocated. These marketing dollars go toward reaching docs at the point of care via sales reps that provide free samples and educational materials for patients, and medical education to doctors and their staff. All pharma brands must be in the practice if they hope to succeed. The last decade has seen an explosion of novel medical technologies and treatments, along with a corresponding increase in the number of reps promoting them. More than 130,000 reps visit the 30,000 busiest medical practices every day. These practices see value in what individual reps deliver, however, they are often overwhelmed by a community of reps that cannot organize itself to fit the practices’ schedules and priorities. In an attempt to control the rep chaos, these practices often dedicate hundreds of staff hours per year to coordinating rep visits on handwritten paper calendars and business cards. With pharma having demonstrated more than a 1000% ROI on such visits, far higher than any other sales/marketing channel, demand for access far outstrips supply. Despite this high demand, more than 30% of these appointments are abandoned by the scheduled rep and go unfilled, a paradox that occurs because: 1. Appointments are booked up to one year in advance by reps that must be in the practice. 2. Rep turnover is high, and territories and physician targets are constantly realigned. 3. Appointment information is locked inside tens of thousands of individual paper calendars. Unfortunately, the burden on staff time and the high rate of “no-show” appointments can lead a practice to reduce rep access to their doctors, or, eliminate it all together. As a result, the most effective channel pharma has to educate doctors about new treatments is becoming a victim of its own success. Enter RxVantage: Our technology enables practices to control the flow of reps in their office without utilizing staff time, which can then be re-focused on patients. Putting the practice back in control empowers them to remain open to receiving the valuable education and services that reps provide. This is especially important given studies showing that physicians not seeing reps are 4X slower to react to new information, both positive (i.e. new standard of care) and negative (i.e. product recall). In addition to keeping the practices’ doors open, RxVantage creates more opportunities for reps within each practice. By freeing the appointment data from the cages of the paper calendars, we apply our innovative technology to every appointment in order to predict and eliminate “no-shows” before they happen. By enabling other reps to book these appointments that otherwise would have been wasted, RxVantage makes the sales forces that call on our medical practices 30% more productive. More than 11,000 reps from 400 companies have used RxVantage to book over 120,000 appointments with 1,200 practices containing 4,000 high-prescribing physicians. At this scale the company has created more than $100MM in value for pharma by virtue of the 40,000+ appointments that would not have occurred in the absence of our technology. In the next 18 months, as new financing allows us to ramp this proven sales process and support the channel partnerships that we have negotiated, the value we create for pharma will exceed $1BB across a network that includes 50,000 physicians. The RxVantage platform includes a dedicated online medical rep scheduling calendar, a communication hub that enables practices to efficiently interact with reps, a sample request tool, up-to-date directory of patient assistance programs, and a drug coupon database.
Animantis, LLC is a software company based in San Diego, California, founded in 2014. It specializes in developing a cloud-based platform that leverages artificial intelligence for drug discovery and development. The platform employs computer vision and machine learning techniques to comprehensively characterize cellular functions, providing medical practitioners with valuable insights that enhance the prediction of drug efficacy and improve in vitro assay design. By maximizing the meaningful interpretation of cellular assays, Animantis aims to guide advancements in medicine and facilitate more effective therapeutic strategies.
Xealth Inc. operates a digital health prescribing platform that allows clinicians to integrate, prescribe, and monitor digital health tools directly from electronic health record (EHR) workflows. Founded in 2016 and based in Seattle, Washington, the platform facilitates patient engagement by enabling care teams to order appropriate digital health tools and programs, which can be sent to patients via email or patient portals. In addition to managing digital health prescriptions, the platform supports patient education and offers non-clinical services such as ride shares and food delivery. This comprehensive approach allows clinicians to monitor patient activity and engagement, ultimately enhancing the overall effectiveness of digital health initiatives within healthcare systems.
Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.
SchoolCare is a digital health platform dedicated to enhancing pediatric healthcare in K-12 public schools. By providing free health technology, it assists school nurses in delivering effective care and ensuring student safety. The platform captures essential health information, including student medical charts, medications, and immunizations, while facilitating communication between schools, families, and healthcare providers. This connectivity allows for timely alerts about health events and supports the efficient operation of public school health programs. By addressing gaps in traditional care coordination, SchoolCare aims to improve health outcomes for children, ensuring that they receive consistent and comprehensive care throughout their school experience.
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.
Aktana Inc. develops AI-enabled marketing decision support software specifically for sales and marketing teams in the life sciences sector. Its primary offerings include the Contextual Intelligence Engine, which allows executives to simulate various call plans and marketing channels, and the Decision Support Engine, which analyzes diverse data sources to provide actionable insights directly within the representatives' workflows. By integrating data-driven suggestions into existing CRM systems, Aktana helps companies refine their strategies and optimize engagement with healthcare professionals. The company's solutions support over 100 brands, including many of the top pharmaceutical companies, by enhancing revenue generation and channel effectiveness. Founded in 2008 and headquartered in San Francisco, Aktana also maintains offices in several global cities, including Tokyo, Shanghai, and Barcelona, positioning itself to understand and address the unique dynamics of the life sciences market.
Mekonos Inc. specializes in the design, development, and production of gene and cell therapies, focusing on a proprietary cell-engineering platform that utilizes advanced silicon technology. Founded in 2017 and based in San Francisco, the company has created an integrated system-on-a-chip, which incorporates micro-electromechanical systems (MEMS) to enable the precise injection of single cells using nanoneedles in a parallel architecture. This innovative approach aims to industrialize genome editing and enhance drug discovery and development processes. Mekonos' technology allows for scalable and reliable manufacturing of engineered therapies aimed at addressing genetic diseases, including various forms of cancer, and supports healthcare providers in delivering diverse therapeutic molecules across multiple cell types.
Pear Therapeutics, Inc. is a healthcare company specializing in the discovery, development, and delivery of software-based therapeutics aimed at treating behavioral health disorders, including addiction, schizophrenia, anxiety, depression, and chronic insomnia. Founded in 2013 and headquartered in Boston, with an additional office in San Francisco, Pear Therapeutics offers a range of digital therapies designed to enhance treatment outcomes. Notable products include reSET, a tool for substance abuse treatment used alongside traditional therapy; reSET-O, which addresses opioid use disorder; and Somryst, aimed at chronic insomnia. The company also provides PearConnect, a patient services center that connects users with advocates, clinicians, and insurance providers to facilitate support and resource access throughout treatment. By integrating digital interventions with pharmaceuticals, Pear Therapeutics aims to improve patient engagement, clinical outcomes, and cost-effectiveness in healthcare.
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.
COTA was founded in 2011 by doctors, engineers, and data scientists to create clarity from fragmented and often-inaccessible real world data. By using proprietary technology, advanced analytics and deep expertise to organize complex data, COTA provides a comprehensive picture of cancer that can be used to advance care and research.
Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. It specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. The company's flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on delivering individualized peripheral nerve stimulation. In addition to its work on essential tremor, the company is also developing therapies for other neurological conditions, including Parkinson's disease, as well as applications in psychiatry, cardiology, and autoimmune disorders.
Science 37, Inc. is a technology-enabled clinical trial company based in Los Angeles, California, focused on advancing biomedical research through innovative, patient-centric models. The company has developed NORA, a cloud-based mobile research platform that facilitates end-to-end networked clinical trial services, allowing researchers to interact with patients and mobile nurses remotely via videos, photographs, and surveys. By utilizing a decentralized approach, Science 37 enhances patient engagement and access, making it possible to reach populations typically underserved by traditional trial methods. The company operates an extensive in-house network of telemedicine investigators and home-health nurses, enabling it to conduct a significant number of virtual interventional trials efficiently. Science 37 serves a diverse clientele, including pharmaceutical companies, device manufacturers, universities, and biotech firms, thereby contributing to the acceleration of clinical research and the development of new treatments.
Omada Health, Inc. is a digital healthcare company that creates and implements online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, Omada Health focuses on helping employers and health plans identify individuals at risk for preventable chronic diseases such as prediabetes, diabetes, hypertension, and heart disease. The company offers personalized programs that adapt to the unique needs of participants, incorporating professional health coaching, connected health devices, and real-time data to foster sustainable lifestyle changes. Omada Health is recognized as the largest provider of the National Diabetes Prevention Program, delivering clinically effective solutions that empower individuals to take charge of their health and achieve their wellness goals.
SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. The company utilizes its proprietary technology platform, SomaScan, which allows for the measurement of proteins with a precision comparable to DNA measurement. This technology enhances the understanding of the molecular bases of health and disease, surpassing traditional genomic methods. SomaLogic develops and offers SOMAmers, modified nucleic acid-based protein-binding reagents, and provides diagnostic tests and protein measurement solutions for various diseases, including those in oncology, neurology, and cardiovascular health. Their products serve multiple applications, including life sciences research, therapeutic drug development, and clinical diagnostics, making significant contributions to the fields of biological and medical sciences. Founded in 1999, SomaLogic continues to advance the capabilities of proteomics in both research and clinical settings.